IL275507B1 - Methods based on the identification of rad51 foci in tumor cells - Google Patents
Methods based on the identification of rad51 foci in tumor cellsInfo
- Publication number
- IL275507B1 IL275507B1 IL275507A IL27550720A IL275507B1 IL 275507 B1 IL275507 B1 IL 275507B1 IL 275507 A IL275507 A IL 275507A IL 27550720 A IL27550720 A IL 27550720A IL 275507 B1 IL275507 B1 IL 275507B1
- Authority
- IL
- Israel
- Prior art keywords
- cells
- cancer
- sample
- level
- subject
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
Claims (34)
1. A method for predicting the response of a subject diagnosed with cancer to an anti-cancertreatment that comprises the use of at least one method that induces DNA damage and/oran agent or combination of agents that target a protein involved in the DNA damageresponse of the cancer cells, comprising:i) determining the level of cells with RAD51 foci in a sample containing tumor cellsisolated from said subject wherein the subject has not received, at 24 hours priorto the isolation of the sample, a chemotherapy selected from the group consistingof AC, FEC, ECF and navelbine/epirubicin, and wherein the sample has not beentreated with a method that induces DNA damage before determining the level ofcells with RAD51 foci, andii) comparing the level obtained in step i) with a reference value, wherein:- a level of cells with RAD51 foci lower than said reference value indicates that thesubject is predicted to respond to the anti-cancer treatment, or- a level of cells with RAD51 foci equal or higher than said reference value, indicatesthat the subject is predicted not to respond to the anti-cancer treatment.
2. A method for selecting a customized therapy for a subject diagnosed with cancer,comprising:i) determining the level of cells with RAD51 foci in a sample containing tumor cellsisolated from said subject, wherein the subject has not received, at 24 hours priorto the isolation of the sample, a chemotherapy selected from the group consistingof AC, FEC, ECF and navelbine/epirubicin, and wherein the sample has not beentreated with a method that induces DNA damage before determining the level ofcells with RAD51 foci, andii) comparing the level obtained in step i) with a reference value, wherein:- a level of cells with RAD51 foci lower than said reference value indicates that thetherapy to be selected comprises the use of at least one method that induces DNAdamage and/or an agent or combination of agents that target the DNA damageresponse of the cancer cells, or 275507/3 - a level of cells with RAD51 foci equal or higher than said reference value indicatesthat the therapy to be selected does not comprise the use of at least one method thatinduces DNA damage and/or an agent or a combination of agents that target theDNA response of the cancer cells.
3. A method for classifying a subject diagnosed with cancer into a patient cohort,comprising:i) determining the level of cells with RAD51 foci in a sample containing tumor cellsisolated from said subject wherein the subject has not received, at 24 hours priorto the isolation of the sample, a chemotherapy selected from the group consistingof AC, FEC, ECF and navelbine/epirubicin, and wherein the sample has not beentreated with a method that induces DNA damage before determining the level ofcells with RAD51 foci, andii) comparing the level obtained in step i) with a reference value, wherein:- a patient is classified into a cohort characterized by responding to an anti-cancertreatment if the level of cells with RAD51 foci is lower than said reference value,or- a patient is classified into a cohort characterized by not responding to an anti-cancertreatment if the level of cells with RAD51 foci is higher than said reference value.
4. A method for predicting whether a tumor from a subject diagnosed with cancer is capableof DNA repair by homologous recombination:i) determining the level of cells with RAD51 foci in a tumor sample, whereinthe tumor has been isolated from a subject that has not received, at 24 hoursprior to the isolation of the tumor, a chemotherapy selected from the groupconsisting of AC, FEC, ECF and navelbine/epirubicin, and wherein thesample has not been treated with a method that induces DNA damagebefore determining the level of cells with RAD51 foci, andii) comparing the level obtained in step i) with a reference value, wherein:- a level of cells with RAD51 foci lower than said reference value is indicative thatthe tumor is capable of DNA repair by homologous recombination, or 275507/3 - a level of cells with RAD51 foci equal or higher than said reference value isindicative that the tumor is not capable of DNA repair by homologousrecombination.
5. The method according to any one of claims 1 to 4 wherein the level of cells with RAD51foci in the sample is determined as the relative level of cells with RAD51 foci with respectto:- the number of tumor cells in the sample,- the number of cells in the sample that are proliferating,- the number of cells in the sample that show DNA damage, preferably doublestrand DNA breaks and- the number of cells in the sample that are proliferating and that show DNAdamage, preferably double strand DNA breaks.
6. The method according to claim 5 wherein the number of cells in the sample that areproliferating is determined by determining the expression of a protein selected from thelist consisting of Geminin, KI-67, Proliferating cell nuclear antigen, Cyclin A2.
7. The method according to claim 6 wherein the selected protein is Geminin.
8. The method according to claim 5 wherein the number of cells in the sample that showdouble strand DNA breaks is determined by the expression in the nucleus of a proteinselected from the list consisting of ɣH2AX, replication protein A (pRPA), p53 Bindingprotein 1 (53BP1), double-strand break repair protein (MRE11).
9. The method according to claim 8, wherein the protein selected is ɣH2AX.
10. The method according to any one of the preceding claims wherein the sample is isolatedfrom blood, saliva, cerebrospinal fluid, urine, stool, bone marrow, a nipple aspirate, or asolid tumor biopsy. 275507/3
11. The method according to any one of the preceding claims wherein the sample is providedas a fixed tissue, paraffin embedded tissue, histological slide, cell suspension, cell pellet,cell slide and/or frozen solid tumor biopsy.
12. The method according to any one of the preceding claims wherein the determination ofthe RAD51 foci, the determination of markers of proliferating cells and/or thedetermination of markers of cells that show double strand DNA breaks is determined byimmunofluorescence or by immunohistochemistry.
13. The method according to any one of claims 1, 2 and 5 to 11 wherein the anti-cancertreatment comprises the use of surgery.
14. The method according to any one of claims 1, 2 and 5 to 11 wherein the agent that targetsthe DNA damage response is a PARP inhibitor.
15. The method according to any one of claims 1, 2 and 5 to 11wherein the agent that targetsthe DNA damage response is selected from the group consisting of chemotherapy andradiotherapy.
16. The method according to any one of claims 1, 2 and 5 to 11 wherein the anti-cancertreatment comprises immunotherapy.
17. The method according to any one of the preceding claims wherein the tumor cells arecharacterized by a loss of function of at least one protein involved in the DNA damageresponse of the cell.
18. The method according to claim 17 wherein at least one protein involved in the DNAdamage response is selected from the group consisting of BRCA1, BRCA2 and/orPALB2.
19. The method according to any one of the preceding claims, wherein the cancer diagnosedin the subject is selected from the list consisting of breast cancer, ovarian cancer, 275507/3 pancreatic cancer, prostate cancer, lung cancer, colorectal cancer, stomach/gastric cancer,endometrial/uterine/cervical cancer, bladder cancer, head and neck cancer, sarcoma,cholangiocarcinoma, glioblastoma, leukemia, multiple myeloma, lymphoma.
20. The method according to any one of the preceding claims wherein the subject from whomthe sample has been isolated has not received any anti-cancer treatment before the sampleis isolated.
21. The method according to any one of claims 1 to 19 wherein the subject from whom thesample has been isolated has received an anti-cancer treatment before the isolation of thesample, wherein the anti-cancer treatment is different from a chemotherapy selected fromthe group consisting of AC, FEC, ECF and navelbine/epirubicin if the patient has receivedthe anti-cancer treatment at 24 hours prior to the isolation of the sample.
22. The method according to claim 21 wherein the anti-cancer treatment is the anti-cancertreatment the response to which is being determined in the method according to any oneof claims 1, 5 to 20.
23. A medicament that comprises an agent that induce directly DNA damage or an agent thattarget a protein involved in the DNA damage response for use in the treatment of a cancerin a subject, further comprising identifying the subject as responder to said medicamentprior to the treatment by the method defined in any one of claims 1 and 5 to 22.
24. The medicament for use according to claim 23 wherein the medicament comprises aPARP inhibitor agent.
25. The medicament for use according to claim 24 wherein the PARP inhibitor agent isselected from the list consisting of olaparib, veliparib, talazoparib, rucaparib, niraparib,CEP-8983, E7016 and BGB-290.
26. The medicament for use according to claim 23, wherein the treatment consists onimmunotherapy. 275507/3
27. The medicament for use according to any one of claims 23-26, wherein the treatment, inaddition to the administration of the medicament, comprises surgery, immunotherapy,chemotherapy, radiotherapy or a combination thereof and wherein the subject has beenidentified as responder to said medicament by a method as defined in any one of claimsand 5 to 19.
28. A medicament that comprises an agent that induce directly DNA damage or an agent thattarget a protein involved in the DNA damage response for use in the treatment of a cancerin a subject, further comprising selecting the treatment by the method defined in any oneof claims 2 and 5 to 22.
29. The medicament for use according to claim 28 wherein the medicament comprises aPARP inhibitor agent.
30. The medicament for use according to claim 29 wherein the PARP inhibitor agent isselected from the list consisting of olaparib, veliparib, talazoparib, rucaparib, niraparib,CEP-8983, E7016 and, BGB-290.
31. The medicament for use according to claim 28, wherein the treatment consists onimmunotherapy.
32. The medicament for use according to any one of claims 28 to 31, wherein the treatment,in addition to the administration of the medicament, comprises surgery, immunotherapy,chemotherapy, radiotherapy or a combination thereof and wherein the treatment has beendesigned by a method as defined in any of claims 2 and 5 to 19.
33. The method according to any one of claims 1 to 22, wherein the method is carried outusing a kit that comprises an antibody that is capable of specifically recognizing theRAD51 protein. 275507/3
34. The method according to claim 33 wherein the kit further comprises an antibody selectedfrom the group consisting of an antibody capable of specifically recognizing the Gemininprotein, and an antibody capable of specifically recognizing the ɣH2AX protein or acombination thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382884.9A EP3502700A1 (en) | 2017-12-21 | 2017-12-21 | Methods based on the detection of rad51 foci in tumor cells |
| PCT/EP2018/086759 WO2019122411A1 (en) | 2017-12-21 | 2018-12-21 | Methods based on the detection of rad51 foci in tumor cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL275507A IL275507A (en) | 2020-08-31 |
| IL275507B1 true IL275507B1 (en) | 2025-08-01 |
| IL275507B2 IL275507B2 (en) | 2025-12-01 |
Family
ID=60954847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL275507A IL275507B2 (en) | 2017-12-21 | 2018-12-21 | Methods based on the detection of rad51 foci in tumor cells |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12007393B2 (en) |
| EP (2) | EP3502700A1 (en) |
| JP (1) | JP7324769B2 (en) |
| KR (1) | KR102626259B1 (en) |
| CN (1) | CN111886499B (en) |
| AU (1) | AU2018387831B2 (en) |
| BR (1) | BR112020012551A2 (en) |
| CA (1) | CA3086794A1 (en) |
| DK (1) | DK3729097T3 (en) |
| ES (1) | ES2975444T3 (en) |
| FI (1) | FI3729097T3 (en) |
| HU (1) | HUE066176T2 (en) |
| IL (1) | IL275507B2 (en) |
| MY (1) | MY206091A (en) |
| PL (1) | PL3729097T3 (en) |
| PT (1) | PT3729097T (en) |
| SG (1) | SG11202005631TA (en) |
| WO (1) | WO2019122411A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114381525A (en) * | 2022-01-20 | 2022-04-22 | 上海交通大学医学院附属第九人民医院 | Group of molecular markers for glioma prognosis typing and typing method and application thereof |
| WO2024089013A1 (en) * | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008066624A2 (en) * | 2006-10-20 | 2008-06-05 | Dana-Farber Cancer Institute | Dna damage repair inhibitors and methods for treating cancer |
| WO2010082821A1 (en) * | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
| US20110288080A1 (en) * | 2006-03-16 | 2011-11-24 | Brown University | Nitrofuran Compounds for the Treatment of Cancer and Angiogenesis |
| US20130210779A1 (en) * | 2012-02-15 | 2013-08-15 | The Washington University | Method of identifying triple negative breast cancer |
| US20160296633A1 (en) * | 2013-07-23 | 2016-10-13 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US20170209594A1 (en) * | 2015-06-25 | 2017-07-27 | Immunomedics, Inc. | Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or parp inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001011369A1 (en) * | 1999-08-10 | 2001-02-15 | Pangene Corporation | Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| JP2011522515A (en) * | 2008-04-10 | 2011-08-04 | マサチューセッツ インスティテュート オブ テクノロジー | Methods for identifying drugs that target cancer stem cells and uses thereof |
| CA2742342A1 (en) * | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| JP6178785B2 (en) * | 2011-04-01 | 2017-08-09 | イェール ユニバーシティーYale University | Cell penetrating anti-DNA antibodies and their use to inhibit DNA repair |
| AU2012274156A1 (en) * | 2011-06-20 | 2014-01-23 | Traslational Cancer Drugs Pharma, S.L. | Method for predicting the clinical response to chemotherapy in a subject with cancer |
| US9810692B2 (en) * | 2012-10-26 | 2017-11-07 | Institut Gustave Roussy | Methods for predicting the sensitivity of a subject to immunotherapy |
| US20140257659A1 (en) | 2013-03-11 | 2014-09-11 | Honda Motor Co., Ltd. | Real time risk assessments using risk functions |
| WO2014194289A1 (en) * | 2013-05-31 | 2014-12-04 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents |
-
2017
- 2017-12-21 EP EP17382884.9A patent/EP3502700A1/en not_active Withdrawn
-
2018
- 2018-12-21 JP JP2020554936A patent/JP7324769B2/en active Active
- 2018-12-21 MY MYPI2020003163A patent/MY206091A/en unknown
- 2018-12-21 EP EP18829880.6A patent/EP3729097B1/en active Active
- 2018-12-21 PL PL18829880.6T patent/PL3729097T3/en unknown
- 2018-12-21 SG SG11202005631TA patent/SG11202005631TA/en unknown
- 2018-12-21 WO PCT/EP2018/086759 patent/WO2019122411A1/en not_active Ceased
- 2018-12-21 US US16/956,112 patent/US12007393B2/en active Active
- 2018-12-21 BR BR112020012551-2A patent/BR112020012551A2/en unknown
- 2018-12-21 CA CA3086794A patent/CA3086794A1/en active Pending
- 2018-12-21 IL IL275507A patent/IL275507B2/en unknown
- 2018-12-21 HU HUE18829880A patent/HUE066176T2/en unknown
- 2018-12-21 DK DK18829880.6T patent/DK3729097T3/en active
- 2018-12-21 KR KR1020207021110A patent/KR102626259B1/en active Active
- 2018-12-21 AU AU2018387831A patent/AU2018387831B2/en active Active
- 2018-12-21 ES ES18829880T patent/ES2975444T3/en active Active
- 2018-12-21 FI FIEP18829880.6T patent/FI3729097T3/en active
- 2018-12-21 CN CN201880087243.XA patent/CN111886499B/en active Active
- 2018-12-21 PT PT188298806T patent/PT3729097T/en unknown
-
2024
- 2024-02-16 US US18/443,660 patent/US20240248088A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110288080A1 (en) * | 2006-03-16 | 2011-11-24 | Brown University | Nitrofuran Compounds for the Treatment of Cancer and Angiogenesis |
| WO2008066624A2 (en) * | 2006-10-20 | 2008-06-05 | Dana-Farber Cancer Institute | Dna damage repair inhibitors and methods for treating cancer |
| WO2010082821A1 (en) * | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
| US20130210779A1 (en) * | 2012-02-15 | 2013-08-15 | The Washington University | Method of identifying triple negative breast cancer |
| US20160296633A1 (en) * | 2013-07-23 | 2016-10-13 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US20170209594A1 (en) * | 2015-06-25 | 2017-07-27 | Immunomedics, Inc. | Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or parp inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| ALHILLI MARIAM M ET AL,, IN VIVO ANTI-TUMOR ACTIVITY OF THE PARP INHIBITOR NIRAPARIB IN HOMOLOGOUS RECOMBINATION DEFICIENT AND PROFICIENT OVARIAN CARCINOMA, 8 September 2016 (2016-09-08) * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200123409A (en) | 2020-10-29 |
| BR112020012551A2 (en) | 2020-11-24 |
| AU2018387831A1 (en) | 2020-07-02 |
| JP7324769B2 (en) | 2023-08-10 |
| PL3729097T3 (en) | 2024-06-24 |
| PT3729097T (en) | 2024-04-15 |
| CN111886499B (en) | 2024-10-29 |
| AU2018387831B2 (en) | 2024-11-21 |
| DK3729097T3 (en) | 2024-02-12 |
| KR102626259B1 (en) | 2024-01-16 |
| WO2019122411A1 (en) | 2019-06-27 |
| IL275507B2 (en) | 2025-12-01 |
| SG11202005631TA (en) | 2020-07-29 |
| US20240248088A1 (en) | 2024-07-25 |
| MY206091A (en) | 2024-11-28 |
| RU2020123914A3 (en) | 2022-05-05 |
| RU2020123914A (en) | 2022-01-21 |
| CN111886499A (en) | 2020-11-03 |
| FI3729097T3 (en) | 2024-04-04 |
| EP3729097A1 (en) | 2020-10-28 |
| CA3086794A1 (en) | 2019-06-27 |
| JP2021508835A (en) | 2021-03-11 |
| ES2975444T3 (en) | 2024-07-05 |
| US12007393B2 (en) | 2024-06-11 |
| IL275507A (en) | 2020-08-31 |
| HUE066176T2 (en) | 2024-07-28 |
| EP3729097B1 (en) | 2024-01-24 |
| EP3502700A1 (en) | 2019-06-26 |
| US20200319182A1 (en) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goertzen et al. | Oral inflammation promotes oral squamous cell carcinoma invasion | |
| Besson et al. | A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker | |
| ES2661238T3 (en) | Biomarkers and methods to determine the efficacy of anti-EGFR antibodies in cancer therapy | |
| Gousias et al. | Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas | |
| Gomez-Roca et al. | Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites | |
| Jakobsen et al. | Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer | |
| Honing et al. | CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy | |
| CN108342482A (en) | A kind of glioblastoma marker and its application, kit | |
| Tini et al. | The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma | |
| Kurbasic et al. | Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases | |
| Yamashita et al. | Correlation among six biologic factors (p53, p21WAF1, MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer | |
| Camacho-Urkaray et al. | Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma-a short report: E. Camacho-Urkaray et al. | |
| Cai et al. | Expression of glucose transporter protein 1 and p63 in serous ovarian tumor | |
| CN105137078A (en) | Kit for predicting pancreatic cancer patient prognosis adverse risks and application thereof | |
| Vandenput et al. | Evolution in endometrial cancer: evidence from an immunohistochemical study | |
| WO2012100573A1 (en) | New molecular marker cuedc2 protein for prognostic determination of breast cancer endocrinology therapy | |
| Gill et al. | Expression of Her-2/neu in colon carcinoma and its correlation with the histological grades and the lymph nodes status | |
| ES2792055T3 (en) | Methods of Detecting a Recurrence of Lung Adenocarcinoma Based on Human Epididymal Protein 4 (HE 4) Marker and Related Uses | |
| Chen et al. | Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer | |
| CN111886499B (en) | Method based on detection of RAD51 foci in tumor cells | |
| JP6695586B2 (en) | Diagnostic agent and kit for use in predicting recurrence risk of pancreatic cancer, and prediction method | |
| Eoli et al. | P11. 19. A macrophages-based immunotherapy of solid tumors microenvironment: the TEM-GBM study (NCT03866109) | |
| Park et al. | Clinicopathologic significance of nuclear factor-κB and vascular endothelial growth factor expression in advanced gastric cancer patients | |
| Zhao et al. | SKA1 expression in oral squamous cell carcinoma and its relationship to P53 and clinicopathologic features | |
| JP6202362B2 (en) | Diagnostic agents and methods for predicting local recurrence risk after breast-conserving breast cancer therapy |